The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 801–900 of 1,006
An overview on the synthetic and medicinal perspectives of indenopyrazoles
Khan, I., Shareef, M. A., & Kumar, C. G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.070 · Cited by 36
Barber, J. S., Scales, S. A., Tran‐Dubé, M., Wang, F., Sach, N. W., Bernier, L., Collins, M. R., Zhu, J., McAlpine, I., & Patman, R. L. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b02029 · Cited by 34
Kumar, M., Dhayabaran, V. V., Sudhapriya, N., Alagumuthu, M., Gideon, D. A., & Annapoorani, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104046 · Cited by 34
Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes
Cullen, J. K., Boyle, G. M., Yap, P.-Y., Elmlinger, S., Simmons, J. L., Broit, N., Johns, J. P., Ferguson, B., Maslovskaya, L. A., Savchenko, A. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80397-9 · Cited by 35
Zhang, C., Hu, Y., Sun, P., Hua, L., Liang, S., Ou, Y., Wu, D., Wu, X., Chen, H. H., Hao, Y., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113417 · Cited by 34
N-heterocycles: Recent Advances in Biological Applications
Dinodia, M. (2021) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x19666211231101747 · Cited by 37
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Liu, F., Chen, J., Li, X., Liu, R., Zhang, Y., Gao, C., & Shi, D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00865 · Cited by 38
Physicochemical profile of macrolides and their comparison with small molecules
Stepanić, V., Žiher, D., Gabelica, V., Jelić, D., Nunhuck, S., Valko, K. L., & Koštrun, S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.11.016 · Cited by 35
Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC
Warmus, J. S., Quinn, C. L., Taylor, C. B., Murphy, S. T., Johnson, T. A., Limberakis, C., Ortwine, D. F., Bronstein, J. C., Pagano, P. J., Knafels, J. D., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.140 · Cited by 34
Fragment library design: efficiently hunting drugs in chemical space
Boyd, S. M., & de Kloe, G. E. (2010) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.11.010 · Cited by 34
Thimm, D., Funke, M., Meyer, A. S., & Müller, C. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4009373 · Cited by 34
Chemical named entity recognition in patents by domain knowledge and unsupervised feature learning
Zhang, Y., Xu, J., Chen, H., Wang, J., Wu, Y., Prakasam, M., & Xu, H. (2016) · Database · doi:10.1093/database/baw049 · Cited by 36
“Medicinal chemistry patents are another important source for text mining approaches to assist in drug development (16), which has been attracting increasing attention from the Pharma and Biotech industries in recent years (17).”
BackgroundFrom UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y2 receptor
Kindon, N. D., Davis, A., Dougall, I. G., Dixon, J., Johnson, T., Walters, I. A. S., Thom, S., McKechnie, K. C. W., Meghani, P., & Stocks, M. J. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.043 · Cited by 37
Shahraki, S., Shiri, F., Majd, M. H., & Dahmardeh, S. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1476266 · Cited by 34
“…normalized by the number of heavy atoms (HA) (Hopkins, Keser€u, Leeson, Rees, & Reynolds, 2014; Kuntz, Chen, Sharp, & Kollman, 1999) Ligand efficiency indices give an indication of the free binding energy per heavy atom and better identify potential drug candidates (Leeson & Springthorpe, 2007).”
BackgroundLinclau, B., Wang, Z., Compain, G., Paumelle, V., Fontenelle, C. Q., Wells, N. J., & Weymouth‐Wilson, A. (2015) · Angewandte Chemie · doi:10.1002/ange.201509460 · Cited by 34
Extracting medicinal chemistry intuition via preference machine learning
Choung, O.-H., Vianello, R., Segler, M., Stiefl, N., & Jiménez-Luna, J. (2023) · Nature Communications · doi:10.1038/s41467-023-42242-1 · Cited by 48
“In addition, we believe it could provide insights into unexplored regions of chemical space currently ignored when applying simpler mnemonics such as Lipinski ’ s rule of fi ve 34,35 .”
Tak1 Selective Inhibition: State of the Art and Future Opportunities
Kilty, I., & Jones, L. H. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.138 · Cited by 33
Diversity-Oriented Synthetic Strategies Applied to Cancer Chemical Biology and Drug Discovery
Collins, I., & Jones, A. M. (2014) · Molecules · doi:10.3390/molecules191117221 · Cited by 36
“These features may be less immediately relevant for chemical tools intended for early cell biology studies, but higher molecular size and lipophilicity are also associated with a greater risk of promiscuous activity [88].”
BackgroundAshton, K. S., Andrews, K. L., Bryan, M. C., Chen, J., Chen, K., Chen, M., Chmait, S., Croghan, M. D., Cupples, R. L., Fotsch, C. H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4016735 · Cited by 33
Dambach, D. M., Misner, D., Brock, M., Fullerton, A. M., Proctor, W. R., Maher, J. M., Lee, D. H., Ford, K. A., & Diaz, D. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00396 · Cited by 37
Sustainable Practices in Medicinal Chemistry Part 2: Green by Design
Aliagas, I., Berger, R., Goldberg, K., Nishimura, R. T., Reilly, J., Richardson, P., Richter, D., Sherer, E. C., Sparling, B. A., & Bryan, M. C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01837 · Cited by 37
Li, Z., Liu, C., Xu, X., Qiu, Q., Su, X., Dai, Y., Yang, J., Li, H., Shi, W., Liao, C., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.001 · Cited by 33
Port, A., Bordas, M., Enrech, R., Pascual, R., Rosés, M., Ràfols, C., Subirats, X., & Bosch, E. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.010 · Cited by 33
Sivakumar, S., Girija, A. S. S., & Jayaseelan, V. P. (2019) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2019.05.003 · Cited by 34
Hossain, S., Sarkar, B., Prottoy, M. N. I., Araf, Y., Taniya, M. A., & Ullah, M. A. (2019) · Modern Research in Inflammation · doi:10.4236/mri.2019.83003 · Cited by 33
“Increased number of rotatable bonds is related with oral bioavailability and it is assumed to be within 10 as acceptable range [30] [31].”
BackgroundModifying the lipophilic part of phenylthiazole antibiotics to control their drug-likeness
Hosny, Y., Abutaleb, N. S., Omara, M., Alhashimi, M., Elsebaei, M. M., Elzahabi, H. S. A., Seleem, M. N., & Mayhoub, A. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111830 · Cited by 35
Wang, R., Chen, Y., Yang, B., Yu, S., Zhao, X., Zhang, C., Hao, C., Zhao, D., & Cheng, M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103474 · Cited by 34
Beck, H., Thaler, T., Meibom, D., Meininghaus, M., Jörißen, H., Dietz, L., Terjung, C., Bairlein, M., von Bühler, C.-J., Anlauf, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00834 · Cited by 38
Li, Z., Wang, X., Xu, X., Yang, J., Qiu, Q., Qiang, H., Huang, W., & Qian, H. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.09.010 · Cited by 33
Valentin, J., Pollard, C. E., Lainée, P., & Hammond, T. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00530.x · Cited by 33
“In silico models have been developed and applied to estimate the potency at the hERG channel, enabling millions of virtual compounds to be screened, thus streamlining chemistry to avoid synthesizing compounds likely to be potent hERG blockers (Gavaghan et al., 2007; Lesson and Springthorpe, 2007).”
BackgroundDiscovery of high affinity inhibitors of Leishmania donovani N -myristoyltransferase
Rackham, M. D., Yu, Z., Brannigan, J. A., Heal, W. P., Paape, D., Barker, K. V., Wilkinson, A. J., Smith, D. F., Leatherbarrow, R. J., & Tate, E. W. (2015) · MedChemComm · doi:10.1039/c5md00241a · Cited by 33
Illig, C. R., Manthey, C. L., Wall, M. J., Meegalla, S. K., Chen, J., Wilson, K. J., Ballentine, S. K., DesJarlais, R. L., Schubert, C. J., Crysler, C. S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200900q · Cited by 33
Kaspersen, S. J., Han, J., Nørsett, K. G., Rydså, L., Kjøbli, E., Bugge, S., Bjørkøy, G., Sundby, E., & Hoff, B. H. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.04.011 · Cited by 35
“Abad-Zapatero and Metz, 2005; Abad-Zapatero, 2007; Leeson and Springthorpe, 2007).”
Identification, Optimization, and Pharmacology of Acylurea GHS-R1a Inverse Agonists
McCoull, W., Barton, P., Brown, A., Bowker, S. S., Cameron, J., Clarke, D. S., Davies, R. D. M., Dossetter, A. G., Ertan, A., Fenwick, M. L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500610n · Cited by 34
Sampat, G. H., Suryawanshi, S. S., Palled, M. S., Patil, A. S., Khanal, P., & Salokhe, A. S. (2022) · Advances in Pharmacology and Pharmacy · doi:10.13189/app.2022.100402 · Cited by 32
Mohanty, S. R., Prusty, N., Nanda, T., Mahulkar, P. S., & Ravikumar, P. C. (2023) · Organic Chemistry Frontiers · doi:10.1039/d3qo01396k · Cited by 34
Sato, K., Takahagi, H., Yoshikawa, T., Morimoto, S., Takai, T., Hidaka, K., Kamaura, M., Kubo, O., Adachi, R., Ishii, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00178 · Cited by 32
Small and colorful stones make beautiful mosaics: fragment-based chemogenomics
de Graaf, C., Vischer, H. F., de Kloe, G. E., Kooistra, A. J., Nijmeijer, S., Kuijer, M., Verheij, M. H. P., ENGLAND, P. J., van Muijlwijk‐Koezen, J. E., Leurs, R., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.12.003 · Cited by 32
Tran, T. D., Wakenhut, F., Pickford, C., Shaw, S. M., Westby, M., Smith‐Burchnell, C., Watson, L., Paradowski, M., Milbank, J. B. J., Brimage, R. A., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201400045 · Cited by 32
Yu, J., Gao, C., Song, Z., Yang, H., & Fu, H. (2015) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201500726 · Cited by 32
Santos, Á., Soares, J. X., Cravo, S. M. M., Tiritan, M. E., Reis, S., Afonso, C., Fernandes, C., & Pinto, M. M. M. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.10.018 · Cited by 32
Nguyen, H. H., Kim, M. B., Wilson, R. J., Butch, C. J., Kuo, K. M., Miller, E. J., Tahirovic, Y. A., Jēčs, E., Truax, V. M., Wang, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00450 · Cited by 32
Finlay, M. R. V., Anderton, M. J., Bailey, A., Boyd, S., Brookfield, J. L., Cairnduff, C., Charles, M. D., Cheasty, A., Critchlow, S. E., Culshaw, J. D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00260 · Cited by 32
Hublikar, M. G., Kadu, V. D., Kumar, J., Raut, D. G., Shirame, S. P., Makam, P., & Bhosale, R. B. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000003 · Cited by 32
Ruddraraju, K. V., Aggarwal, D., Niu, C., Baker, E. A., Zhang, R., Wu, L., & Zhang, Z. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00302 · Cited by 33
Udvarhelyi, A., Rodde, S., & Wilcken, R. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00337-7 · Cited by 34
Ray, P. C., Huggett, M., Turner, P. A., Taylor, M., Cleghorn, L. A. T., Early, J. V., Kumar, A., Bonnett, S. A., Flint, L., Joerss, D., et al. (2021) · ACS Omega · doi:10.1021/acsomega.0c05589 · Cited by 34
Chemical and Structural Strategies to Selectively Target mTOR Kinase
Borsari, C., Pascale, M. D., & Wymann, M. P. (2021) · ChemMedChem · doi:10.1002/cmdc.202100332 · Cited by 34
Elbadawi, M. M., Khodair, A. I. A., Awad, M. K., Kassab, S. E., El‐Saadi, M. T., & Abdellatif, K. R. A. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131574 · Cited by 33
Transition‐Metal‐Free Synthesis of N‐Heterocyclic Compounds via Multi‐Component Reactions
Boruah, D. J., Borkotoky, L., Newar, U. D., Maurya, R. A., & Yuvaraj, P. (2023) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202300297 · Cited by 32
Pettersson, M., Johnson, D. S., Subramanyam, C., Bales, K. R., Ende, C. W. A., Fish, B. A., Green, M., Kauffman, G. W., Lira, R., Mullins, P. B., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.059 · Cited by 32
Fukunaga, K., Sakai, D., Watanabe, K., Nakayama, K., Kohara, T., Tanaka, H., Sunada, S., Nabeno, M., Okamoto, M., Saito, K.-I., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.005 · Cited by 32
Ingólfsson, H. I., Sanford, R. L., Kapoor, R., & Andersen, O. S. (2010) · Journal of Visualized Experiments · doi:10.3791/2131 · Cited by 32
Gilbert, I. H. (2013) · Parasitology · doi:10.1017/s0031182013001017 · Cited by 32
“LogP in particular appears to be correlated to a number of developability issues, including toxicity, metabolic instability and insolubility (Leeson and Springthorpe, 2007; Hughes et al. 2008; Hann, 2011).”
BackgroundFluorine multipolar interaction: Toward elucidating its energetics in binding recognition
Li, X., Keefer, C. E., & Brown, M. F. (2016) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2016.12.013 · Cited by 32
Engel, J., Smith, S. P., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00515 · Cited by 36
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design
Meine, R., Becker, W. B., Falke, H., Preu, L., Loaëc, N., Meijer, L., & Kunick, C. (2018) · Molecules · doi:10.3390/molecules23020064 · Cited by 34
“LLE is calculated from pIC50 minus calculated logP [46].”
MethodBandarage, U. K., Cao, J., Come, J. H., Court, J. J., Gao, H., Jacobs, M. D., Marhefka, C. A., Nanthakumar, S., & Green, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.040 · Cited by 32
Sharma, G., Kumar, N., Sharma, C. S., Alqahtani, T., Tiruneh, Y. K., Sultana, S., Silva, G. V. R., Menezes, G. D. L., Zaki, M. E. A., & Oliveira, J. I. N. (2025) · Scientific Reports · doi:10.1038/s41598-025-86016-9 · Cited by 37
Ståhl, M., & Baier, S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500091 · Cited by 31
Hung, A. W., Silvestre, H. L., Wen, S., George, G. P. C., Boland, J. A., Blundell, T. L., Ciulli, A., & Abell, C. (2015) · ChemMedChem · doi:10.1002/cmdc.201500414 · Cited by 32
Ryabukhin, S. V., Panov, D. M., Granat, D. S., Ostapchuk, E. N., Kryvoruchko, D. V., & Grygorenko, O. O. (2014) · ACS Combinatorial Science · doi:10.1021/co4001277 · Cited by 31
Striking essential oil: tapping into a largely unexplored source for drug discovery
Feyaerts, A. F., Luyten, W. H. M. L., & Dijck, P. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59332-5 · Cited by 32
Synthetic product-based approach toward potential antileishmanial drug development
Pal, R., Teli, G., Akhtar, M. J., & Matada, G. S. P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115927 · Cited by 31
Abbott Physicochemical Tiering (APT)—A unified approach to HTS triage
Cox, P. B., Gregg, R. J., & Vasudevan, A. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.047 · Cited by 31
Design and Synthesis of Diazatricyclodecane Agonists of the G‑Protein-Coupled Receptor 119
Darout, E., Robinson, R. P., McClure, K. F., Corbett, M. S., Li, B., Shavnya, A., Andrews, M. P., Jones, C. S., Qifang, L., Minich, M. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301626p · Cited by 31
Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor
Abberley, L., Bebius, A., Beswick, P., Billinton, A., Collis, K. L., Dean, D. K., Fonfría, E., Gleave, R. J., Medhurst, S. J., Michel, A. D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.101 · Cited by 31
Pettersson, M., Johnson, D. S., Subramanyam, C., Bales, K. R., Ende, C. W. A., Fish, B. A., Green, M., Kauffman, G. W., Mullins, P. B., Navaratnam, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401782h · Cited by 33
Lange, J. H. M., van der Neut, M. A. W., Wals, H. C., Kuil, G. D., Borst, A. J. M., Mulder, A. T., den Hartog, A. P., Zilaout, H., Goutier, W., van Stuivenberg, H. H., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.032 · Cited by 33
Zhang, L., Brodney, M. A., Candler, J., Doran, A. C., Duplantier, A. J., Efremov, I. V., Evrard, E., Kraus, K. G., Ganong, A. H., Haas, J. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101414h · Cited by 34
Ryabukhin, S. V., Panov, D. M., Plaskon, A. S., & Grygorenko, O. O. (2012) · ACS Combinatorial Science · doi:10.1021/co300082t · Cited by 31
Edwards, C. D., Luscombe, C. N., Eddershaw, P. J., & Hessel, E. M. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1983-4 · Cited by 31
Nakano, H., Hasegawa, T., Kojima, H., Okabe, T., & Nagano, T. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00518 · Cited by 31
Alagumuthu, M., Muralidharan, V. P., Andrew, M., Ahmed, M. H., Iyer, S. K., & Arumugam, S. (2018) · Molecular Informatics · doi:10.1002/minf.201800048 · Cited by 31
Brustolin, L., Nardon, C., Pettenuzzo, N., Fantoni, N. Z., Quarta, S., Chiara, F., Gambalunga, A., Trevisan, A., Marchiò, L., Pontisso, P., et al. (2018) · Dalton Transactions · doi:10.1039/c8dt02965b · Cited by 32
Pyrazole NNRTIs 3: Optimisation of physicochemical properties
Mowbray, C. E., Corbau, R., Hawes, M., Jones, L. H., Mills, J. E. J., Perros, M., Selby, M. D., Stupple, P. A., Webster, R., & Wood, A. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.043 · Cited by 31
Oliveira, M. D., Cenzi, G., Nunes, R. R., Andrighetti, C. R., Valadão, D. D. S., Reis, C. D., Simões, C. M. O., Nunes, R. D. C., Júnior, M., Taranto, A. G., et al. (2013) · Molecules · doi:10.3390/molecules181215276 · Cited by 32
“The Lipinski’s ‘Rule of Five’ [24] as well as other parameters like lipophilic efficiency (LipE) [25] have been shown to be useful tools to aid in choosing oral drug candidates.”
Terpenes as Potential Anti-Alzheimer’s Disease Agents
Lima, E., & Medeiros, J. (2024) · Applied Sciences · doi:10.3390/app14093898 · Cited by 34
Foster, R. W., Benhamou, L., Porter, M. J., Bučar, D., Hailes, H. C., Tame, C. J., & Sheppard, T. D. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201406286 · Cited by 30
Loureiro, D. R. P., Soares, J. X., Lopes, D., Macedo, T., Yordanova, D., Jakobtorweihen, S., Nunes, C., Reis, S., Pinto, M. M. M., & Afonso, C. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.01.029 · Cited by 31
Entanglement of CCR5 and Alzheimer’s Disease
Li, T., & Zhu, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00209 · Cited by 36
Diallo, B. N., Swart, T., Hoppe, H. C., Bishop, Ö. T., & Lobb, K. A. (2021) · Scientific Reports · doi:10.1038/s41598-020-80722-2 · Cited by 34
Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets
Romeo, I., Mesiti, F., Lupia, A., & Alcaro, S. (2021) · Molecules · doi:10.3390/molecules26030632 · Cited by 34
“4, and the increase of lipophilicity property can result in a probable lack of selectivity and attrition in drug development [86].”
BackgroundTamayo, N. A., Bourbeau, M. P., Allen, J. R., Ashton, K. S., Chen, J. J., Kaller, M. R., Nguyen, T. T. H., Nishimura, N., Pettus, L. H., Walton, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02030 · Cited by 32
Ruf, S. G., Rajagopal, S., Kadnur, S. V., Hallur, M. S., Rani, S., Kristam, R., Srinivasan, S., Zope, B. R., Gondrala, P. K., Swamy, I. N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19634-2 · Cited by 30
An Insight on the Prospect of Quinazoline and Quinazolinone Derivatives as Anti-tubercular Agents
Kushwaha, N., Sahu, A., Mishra, J., Soni, A., & Dorwal, D. (2023) · Current Organic Synthesis · doi:10.2174/1570179420666230316094435 · Cited by 34
meta-Selective O-Arylation of Cyclic Diaryliodonium Salts with Phenols via Aryne Intermediates
Liu, M., Jiang, H., Tang, J., Ye, Z., Zhang, F., & Wu, Y. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c00600 · Cited by 30
Kell, D. B., & Dobson, P. D. (2009) · Research Explorer (The University of Manchester) · Cited by 31
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors
Hu, H., Wang, X., Chan, G. K. Y., Chang, J. H., Do, S., Drummond, J., Ebens, A. J., Lee, W., Ly, J., Lyssikatos, J. P., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.052 · Cited by 30
Sato, K., Sugimoto, H., Rikimaru, K., Imoto, H., Kamaura, M., Negoro, N., Tsujihata, Y., Miyashita, H., Odani, T., & Murata, T. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.01.028 · Cited by 30
Advances in fragment-based drug discovery platforms
Orita, M., Warizaya, M., Amano, Y., Ohno, K., & Niimi, T. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903317580 · Cited by 35
“LLE pKi - cLogP (or LogD) Metric of acceptable lipophilicity per unit of in vitro potency [109]”
BackgroundThe development of CNS-active LRRK2 inhibitors using property-directed optimisation
Kavanagh, M. E., Doddareddy, M. R., & Kassiou, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.086 · Cited by 31
A framework for grouping nanoparticles based on their measurable characteristics
Sayes, C. M., Smith, & Ivanov (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s40521 · Cited by 30
O’Hagan, D., & Young, R. J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511055 · Cited by 30
Discovery of 2H-Chromen-2-one Derivatives as G Protein-Coupled Receptor-35 Agonists
Wei, L., Wang, J., Zhang, X., Wang, P., Zhao, Y., Li, J., Hou, T., Qu, L., Shi, L., Liang, X., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01431 · Cited by 30
Liu, Z., Lei, Q., Wei, W., Xiong, L., Shi, Y., Yan, G., Gao, C., Ye, T., Wang, N., & Yu, L. (2017) · RSC Advances · doi:10.1039/c7ra02518a · Cited by 30
Physical Properties in Drug Design
Young, R. J. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2013_35 · Cited by 40
Grasso, D., Galderisi, S., Santucci, A., & Bernini, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065819 · Cited by 33
“reaching a variety of tissues [20], and oral availability [21].”
BackgroundKibet, S., Kimani, N. M., Mwanza, S. S., Mudalungu, C. M., Santos, C. B. R., & Tanga, C. M. (2024) · Pharmaceuticals · doi:10.3390/ph17040510 · Cited by 29
Jennings, L. E., Measures, A. R., Wilson, B. G., & Conway, S. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.197 · Cited by 32
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.